Scott Kelly
Senior Director, Oncology Real-World Evidence & Epidemiology Lead Pfizer
Scott Kelly is Oncology Real-World Evidence (RWE) & Epidemiology Lead at Pfizer, where he oversees a multidisciplinary team supporting evidence generation across pre-clinical, clinical development, and post-marketing studies. With deep expertise in pharmacoepidemiology, oncology, and real-world data, Scott specialises in integrating clinical, genomic, and registry data to inform benefit–risk assessments and advance patient outcomes. His work spans machine learning–driven risk prediction, safety studies, and epidemiologic strategy across multiple therapeutic areas. Scott is particularly focused on leveraging innovative data and partnerships to accelerate impactful, evidence-driven decision-making in oncology.
Seminars
- Applying AI and machine learning to real‑world data to improve risk prediction, safety signal detection, and benefit–risk assessment across development and post‑marketing
- Understanding why AI‑driven analyses often fail to translate into trusted evidence, particularly when uncertainty, bias, or poor contextualization limit interpretation in regulatory and safety settings
- Aligning AI‑enabled RWE with epidemiological principles and regulatory expectations to ensure outputs are interpretable, credible, and decision‑relevant
